Health & Social /

The unhealthy truth about Ireland’s drugs deficit

The unhealthy truth about Ireland’s drugs deficit

Irish patients have access to fewer new medicines than those in other EU countries – and they wait longer to get them

HSE interim chief in running for €300k director general role

HSE interim chief in running for €300k director general role

Memo outlined risks of St James’s Children’s Hospital plan in 2012

Memo outlined risks of St James’s Children’s Hospital plan in 2012

A cabinet memorandum told ministers seven years ago that locating the new hospital at St James’s campus would be costlier and take longer

Sláintecare team wanted to get out of ‘troubled’ Department of Health

Sláintecare team wanted to get out of ‘troubled’ Department of Health

Sláintecare strategy: show us the money

Sláintecare strategy: show us the money

Two years after it was conceived as an idea, we have an action plan for reform of the health system. Many critics say this is too little too late, with suspiciously little detail on where the funding is to come from for the ten-year plan

No GP at one in five primary care centres

No GP at one in five primary care centres

‘Shocking’ figures show little progress made in planned Sláintecare reform programme

Skin Deep: the rise of cosmeceuticals

Skin Deep: the rise of cosmeceuticals

With skincare brands making ever more ‘scientific’ claims about the anti-ageing benefits of their products, where does the truth lie? Susan Mitchell investigates

Political inertia prevents the state from building an efficient health service

Political inertia prevents the state from building an efficient health service

The HSE is on a merry-go-round of budgetary despair, and only politicians can stop it

Biosimilar drugs offer a savings opportunity that we must take

Biosimilar drugs offer a savings opportunity that we must take

A dramatic increase in the prescribing of cheaper biosimilar medicines is required to enable us to afford costly new cancer and other therapies

Price still isn’t right for Biogen’s blockbuster drug

Price still isn’t right for Biogen’s blockbuster drug

HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion

Doctors will have to prescribe cheaper drugs under new plans

Doctors will have to prescribe cheaper drugs under new plans

Stephen Kinsella on health spending

Stephen Kinsella on health spending

Our system is geographically unequal. Where you are born really matters. Our outcomes from our health system are measurably worse than in other countries, and our spending per person is as high as Denmark’s. Why is that?

The silent majority of health betrayals

The silent majority of health betrayals

In all the noise surrounding the Children’s Hospital fiasco, a multitude of other broken promises have been swept under the carpet

Blackrock Medical in sale and lease back bid for children’s hospital

Blackrock Medical in sale and lease back bid for children’s hospital

Under the proposal, which was made to finance minister Paschal Donohoe, Blackrock Medical said it was interested in purchasing the property and buildings. It said the HSE could then enter into a lease for a 25-50 year term

HSE has ‘almost exhausted’ its 2019 funding for new drugs

HSE has ‘almost exhausted’ its 2019 funding for new drugs

Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), was speaking after the HSE informed Biogen, manufacturer of Spinraza, it would not fund the drug